PMA supplement
P110027 S018: therascreen® KRAS RGQ PCR Kit
FDA PMA supplement · Normal 180 Day Track · QIAGEN GmbH
Key facts
| Original PMA | P110027 |
|---|---|
| Supplement number | S018 |
| Supplement type | Normal 180 Day Track |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | therascreen® KRAS RGQ PCR Kit |
| Generic name | Somatic gene mutation detection system |
| Applicant | QIAGEN GmbH |
| Product code | OWD |
| Received date | Jun 3, 2024 |
| Decision date | Jan 16, 2025 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: